ライフサイエンスコーパス: prognosis

1 th TTP and CLOVAR mesenchymal profile (worst prognosis).

2 the course that the disease takes over time (prognosis).

3 ated with an advanced tumor state and a poor prognosis.

4 derstanding of retinal disease diagnosis and prognosis.

5 end-stage liver disease and portends a poor prognosis.

6 und in tumor samples from patients with poor prognosis.

7 expression, frequent metastasis and a dismal prognosis.

8 dontitis and assign a periodontal/prosthetic prognosis.

9 ted with more aggressive phenotypes and poor prognosis.

10 ytotoxic T cell activation, and poor patient prognosis.

11 f neo-lymphangiogenesis that defines patient prognosis.

12 CB in diabetic SCI rats, leading to improved prognosis.

13 terizes a subgroup of HCC patients with poor prognosis.

14 CC associated with a favorable developmental prognosis.

15 sion Children with metastatic HB have a poor prognosis.

16 d RUNX1 mutations are associated with a poor prognosis.

17 ly distinct subtype of CRC with an excellent prognosis.

18 B) types, which may more accurately estimate prognosis.

19 with colorectal cancer (CRC) metastasis and prognosis.

20 C) is increasing in incidence and has a poor prognosis.

21 ative Pe blood predicted a trend toward poor prognosis.

22 human cancers and is associated with a poor prognosis.

23 immunoexpression showed a trend toward poor prognosis.

24 an inflammatory molecular signature and poor prognosis.

25 prone to have poor differentiation and poor prognosis.

26 lecular features and how they affect patient prognosis.

27 and its upregulation is associated with poor prognosis.

28 nd colon cancer and was associated with poor prognosis.

29 n acute heart failure (HF) and portends poor prognosis.

30 e they have been associated with a favorable prognosis.

31 djuvant chemotherapy fails to improve a poor prognosis.

32 hypervascular primary brain tumor with poor prognosis.

33 on, ventricular arrhythmic burden, and worse prognosis.

34 f primary malignant brain tumors with dismal prognosis.

35 a potential marker for cancer diagnosis and prognosis.

36 higher VDR expression was linked with better prognosis.

37 have all linked BCR on CLL cells to disease prognosis.

38 der to diagnose patients and monitor disease prognosis.

39 e-8 expression levels correlate with a worse prognosis.

40 n gastric cancer and is associated with poor prognosis.

41 t has unknown significance to oncogenesis or prognosis.

42 (NEC - neuroednocrine carcinoma) with a poor prognosis.

43 nal class, pathophysiological processes, and prognosis.

44 nflammation, predisposing patients to a poor prognosis.

45 appaB) p65-->ZEB1 pathway and confers a poor prognosis.

46 he Milan criteria, 287 had demonstrably good prognosis.

47 s of pro-inflammatory cytokines predict poor prognosis.

48 reby favorably affecting patients' long-term prognosis.

49 e of the deadliest cancers, with a very poor prognosis.

50 termine the effect of nodal sterilization on prognosis.

51 ter a breast cancer diagnosis to an improved prognosis.

52 gene-expression cohorts, and correlated with prognosis.

53 lung cancer (NSCLC) are associated with poor prognosis.

54 ession is linked to high metastasis and poor prognosis.

55 ggressive disease, drug resistance, and poor prognosis.

56 s associated with high-risk disease and poor prognosis.

57 stic evaluation and criteria, treatment, and prognosis.

58 low differentiation showed relatively worse prognosis.

59 rasound, a modality routinely used to assess prognosis.

60 icant detrimental association with patients' prognosis.

61 ncy in human tumors and correlates with poor prognosis.

62 ression correlates with disease severity and prognosis.

63 e spreading as a potential indicator of poor prognosis.

64 clinical parameters affecting treatment and prognosis.

65 poietic stem cell transplantation has a poor prognosis.

66 as increased in human CRC and predicted poor prognosis.

67 seful as biomarkers for cancer diagnosis and prognosis.

68 nd therapy response and usually predict poor prognosis.

69 ed RC, SRCC patients had significantly worse prognosis.

70 ype natriuretic peptide levels, and a poorer prognosis.

71 erminant of cancer progression potential and prognosis.

72 oesophageal adenocarcinoma, which has a poor prognosis.

73 icular function resulting in a poor clinical prognosis.

74 expression was associated with poor patient prognosis.

75 DAC) is an aggressive malignancy with a poor prognosis.

76 ression is negatively correlated with cancer prognosis.

77 x disease that is associated with an adverse prognosis.

78 0.3%) were QPL related; 20 (12.7%) addressed prognosis.

79 reatment, risk stratification, and assessing prognosis.

80 k of complications, and thus, to improve the prognosis.

81 procedures for eyes with a favorable visual prognosis.

82 man solid tumors and is associated with poor prognosis.

83 w miR-383 expression is associated with poor prognosis.

84 pear to be associated with worse medium-term prognosis.

85 nearly three times more likely to ask about prognosis (16.7% v 5.8%; P =.03).

86 DLBCL and MCL had a poor prognosis (5-year DSS, 21% and 50%, respectively), where

87 tively), whereas EMZL, FL, and MF had a good prognosis (5-year DSS, 88%, 88% and 86%, respectively).

88 e relationship between procedural volume and prognosis after percutaneous coronary intervention (PCI)

89 Milan criteria, 2714 were shown to have poor prognosis after transplantation after stratification by

90 splantation models, and correlates with poor prognosis among breast cancer patients.

91 a overexpression, which correlated with poor prognosis and also discriminated infiltrating mesenchyma

92 ccurs in the early stages of SCI and affects prognosis and cell survival.

93 ogenic autoimmunity is crucial for patients' prognosis and clinical management.

94 Assigning a periodontal prognosis and determining the severity of periodontitis

95 g the sensor potentially useful for both the prognosis and diagnosis of cancer in clinical applicatio

96 the three VAV1 CpGs serve as biomarkers for prognosis and early detection, and the TGFbeta-VAV1 axis

97 tions in PDGF receptors are markers of worst prognosis and efficient targeting of these receptors is

98 ioma is a highly aggressive cancer with poor prognosis and few treatment options following progressio

99 ounselling of these patients regarding their prognosis and for establishing the most appropriate dise

100 disease course has implications for clinical prognosis and for stratification of participants in clin

101 ratification of the cancers according to its prognosis and further response to drug treatment.

102 progression and is strongly related to poor prognosis and high mortality risk.

103 cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but there re

104 = 99 patients), TF was associated with poor prognosis and increased risk of blood vessel infiltratio

105 maging to yield information regarding cancer prognosis and likelihood of therapeutic response.

106 (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options.

107 e B intramural hematomas (IMH), with unclear prognosis and management.

108 , yet scarce evidence is available about its prognosis and natural history, which are crucial to info

109 is a chronic fatal lung disease with dismal prognosis and no cure.

110 rare opportunistic bacterial infection, but prognosis and outcome of these patients are poorly defin

111 stablish the clinical values of LncHIFCAR in prognosis and potential therapeutic strategy for oral ca

112 Epithelial ovarian cancer (EOC) has poor prognosis and rapid recurrence because of widespread dis

113 AS mutation is commonly associated with poor prognosis and resistance to therapy.

114 the results of molecular profiling to guide prognosis and selection of actionable therapeutic target

115 cancer was positively associated with better prognosis and sensitivity to chemotherapy and can potent

116 prediction model that effectively predicted prognosis and survival (P < 0.001).

117 progression, with potential implications for prognosis and therapeutic intervention.

118 Elevated MPV might act as a marker of prognosis and therapeutic target for CRC.

119 sion levels in patient CTC's correlated with prognosis and therapy response.

120 sion, with potential implications for cancer prognosis and therapy.

121 ests its potential as a biomarker for cancer prognosis and therapy.

122 generation (nAMD) is essential in discussing prognosis and treatment options with patients and to sup

123 as a robust biomarker for the prediction of prognosis and treatment response in breast and ovarian c

124 termine subphenotypes within AD that predict prognosis and treatment responses.

125 re as potential biomarkers for breast cancer prognosis and treatment.

126 mutations such as KRAS, may prove useful for prognosis and understanding of tumor biology.

127 inct phenotypes and endotypes of CRS affects prognosis and, most importantly, is necessary as the bas

128 urther effective therapeutic targets, better prognosis, and improved outcomes.

129 ith acute myeloid leukemia (AML) have a poor prognosis, and innovative maintenance therapy could impr

130 erity and helps in the detection, diagnosis, prognosis, and management of HF.

131 logous stem-cell transplantation have a grim prognosis, and new treatments for these patients are cle

132 e of disease relative to diagnosis, staging, prognosis, and response to treatment.

133 l cell carcinoma (RCC) is a cancer with poor prognosis, and the 5-year survival rate of patients with

134 n with clinical relevance for the diagnosis, prognosis, and therapy of patients.

135 Both heterogeneity of classical MPNs and prognosis are determined by a specific genomic landscape

136 low MFN2 expression are associated with poor prognosis as compared to patients with high MFN2 express

137 clinical treatment decisions affecting tooth prognosis (as measured by defect fill, improvements in b

138 hese results also explain the more favorable prognosis associated with retention of TRM cells in the

139 A VC within normal range suggested a good prognosis at 3 months but was of little other value.

140 gnosis of stage III disease conveyed a worse prognosis at each conditional survival time point.

141 s during the acute phase of illness had poor prognosis at the post-acute phase with more restricted j

142 R mutants expressing TP53 (n = 5) had a good prognosis based on CANARY features.

143 Prognosis based on the available clinical and imaging in

144 reast tumor is usually accompanied by a poor prognosis because of the metastasis of tumor cells.

145 cinoma (OSCC) patients generally have a poor prognosis, because of the invasive nature of these tumor

146 a lower heart rate is associated with better prognosis, but only for those in sinus rhythm.

147 l adenocarcinoma (PDAC) has generally a poor prognosis, but recent data suggest that there are molecu

148 ELBW infants with EOD have a very poor prognosis compared to those with LOD.

149 both is associated with significantly worse prognosis compared with either one of them.

150 er chromosomes were associated with a poorer prognosis compared with other non-CBF aberrant karyotype

151 ions as short as 3 months had improved renal prognosis compared with patients who relapsed.

152 ded development into a marker and target for prognosis, detection, and treatment of invasive prostate

153 uable for the design of peptide-based cancer prognosis, diagnosis and treatment.

154 (MALA), a severe medical condition with poor prognosis, especially in individuals with renal dysfunct

155 Genetic diagnosis can help predict prognosis, especially with regard to arrhythmia risk for

156 We assess long-term outcome and prognosis factors for vascular complications in patients

157 ndrolone improved outcomes irrelevant to all prognosis factors.

158 rs of posttransplant HCC recurrence, data on prognosis following recurrence are scarce.

159 at high TNC expression correlates with worse prognosis for lung adenocarcinoma, and that a three-gene

160 inal aortic aneurysm might be worse than the prognosis for men.

161 tion to salvage vision in patients with poor prognosis for other corneal procedures.

162 ulation-based estimates of the incidence and prognosis for patients with brain metastases at time of

163 ne and chelation therapy give hope of better prognosis for patients, but successful translation to cl

164 , lymph node positivity (LNP) indicates poor prognosis for survival and is central to radiotherapy pl

165 d worse prognosis versus no change or better prognosis for TM, based on the postscan assessment.

166 Prognosis for women with abdominal aortic aneurysm might

167 ly ill patients respond to information about prognosis from palliative care clinicians.

168 PRES has a favourable prognosis generally, but neurological sequelae and even

169 ith characteristic symptoms/signs and a good prognosis had stabilized.

170 rs that could inform an individual's disease prognosis have been replicated in multiple cohorts: base

171 ting Merkel cell carcinoma viral status with prognosis have inconsistent findings.

172 PDAC size was associated with worse prognosis (hazard ratio 1.26, P = 0.02), together with C

173 re-expressed by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often associat

174 ity, epithelial-mesenchymal transition, poor prognosis; (iii) CRIS-C: elevated EGFR signalling, sensi

175 and alpha-internexin was correlated with the prognosis in 2 independent collectives of patients with

176 t nKIFC1 WI an independent biomarker of poor prognosis in AA TNBC patients, potentially due to the ne

177 4 were significantly associated with a worse prognosis in acute myeloid leukemia, breast cancer, glio

178 acknowledged as a criterion for establishing prognosis in all stages of disease.

179 Stem cell gene signatures predict poor prognosis in AML patients; however, with few exceptions,

180 nd S100A8 expression has been linked to poor prognosis in AML.

181 We investigated its role on prognosis in anticoagulated atrial fibrillation (AF) pat

182 that mutated CSMD3 is associated with better prognosis in Asian patients.

183 sis, pre-metastatic niche formation and poor prognosis in breast cancer patients.

184 eceptor (ERalpha-36), associated with a poor prognosis in breast cancers.

185 t circulating tumor markers as predictors of prognosis in chemotherapy-naive patients with advanced N

186 and TP53 mutations are associated with poor prognosis in chronic lymphocytic leukaemia (CLL).

187 (CRT) therapy and carries a relatively poor prognosis in comparison with HPV-positive disease, with

188 el tissue biomarkers of disease severity and prognosis in conjunctival fibrosis after glaucoma surger

189 urine synthetic enzymes correlated with poor prognosis in glioblastoma patients.

190 her malignancies and is associated with poor prognosis in leukemia patients.

191 xpression significantly correlated with poor prognosis in LUAD but not in SCC.

192 t Ino80B, negatively correlates with disease prognosis in lung cancer patients.

193 correlates with poor therapeutic response or prognosis in many solid tumors, including BC.

194 s been proposed as a surrogate for long-term prognosis in membranous nephropathy (MGN), variability i

195 ith chemoresistance, aggressiveness and poor prognosis in NSCLC patients.

196 e metabolic aberrations responsible for poor prognosis in ovarian cancer.

197 lmonary arterial compliance may also predict prognosis in PAH.

198 imidine biosynthesis, correlates with better prognosis in pancreatic cancer patients on fluoropyrimid

199 ciated with chemotherapy resistance and poor prognosis in patients with acute myeloid leukemia (AML),

200 om them have been reported to correlate with prognosis in patients with epithelial ovarian cancer (EO

201 (SGM+) has also been associated with a worse prognosis in patients with IA, and genetic determinants

202 clinical and imaging grading scale for acute prognosis in patients with PICH.

203 ciated with increased tumor volumes and poor prognosis in PDAC especially combined with high levels o

204 eptor CCR4 in tumors is associated with poor prognosis in several cancers.

205 n, SRCC was an independent predictor of poor prognosis in stage III RC patients, but not in stage II.

206 ining sudden cardiac arrest pathogenesis and prognosis in survivors.

207 s with functional testing (FT) in estimating prognosis in symptomatic patients.

208 novel potential for informing diagnosis and prognosis in the unresponsive wakeful syndrome and minim

209 expression as a candidate biomarker of poor prognosis in TNBC, and they offer a preclinical proof of

210 er percutaneous coronary intervention, their prognosis is comparable to that of the general populatio

211 Its visual and systemic prognosis is particularly poor compared with vitreoretin

212 PEL prognosis is poor and patients barely survive >6 months

213 The prognosis is poor and the five-year survival rate ranges

214 When symptoms develop, prognosis is poor, and current guidelines recommend prom

215 Prognosis is poor, in part, because existing medications

216 n between obesity and breast cancer risk and prognosis is well established in estrogen receptor (ER)-

217 ate a therapeutic vulnerability in this poor-prognosis leukemia.

218 Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high mortality

219 0.7% vs 28.3%; IQR, 25.5%-31.4%; P = .60) or prognosis (log-rank 0.8; P = .38).

220 amous lung tumours, which are extremely poor prognosis, may result from cellular plasticity.

221 ancer prognostic characteristics and patient prognosis, most prominently among premenopausal women.

222 of acute myeloid leukemia (AML) and its poor prognosis necessitate therapeutic improvement.

223 the association between thyroid hormones and prognosis of acute ischemic stroke (AIS) reported confli

224 ing the utility of thyroid hormone levels in prognosis of acute stroke.

225 d therapy intensification abrogates the poor prognosis of adult ETP-ALL.

226 ance the clinical diagnosis, management, and prognosis of AKI through the combined use of available c

227 ally repressed in cancers and signifies poor prognosis of breast cancer patients.

228 ance, immune evasion, and ultimately to poor prognosis of cancer patients.

229 Prognosis of ChHD patients is worse compared with other

230 n associated with progression, severity, and prognosis of chronic inflammatory diseases and a multitu

231 PET-CT is a powerful tool to evaluate the prognosis of de novo myeloma.

232 The prognosis of EAC remains poor because it is usually diag

233 , which may also play important roles in the prognosis of EC patients, has not been extensively studi

234 e invasive tumor front and predicts for poor prognosis of esophageal SCC, shedding light upon the tum

235 iltration of CD11b(+)/CD163(+) TAMs and poor prognosis of GBM patients.

236 ive blood-based method for the diagnosis and prognosis of hepatocellular carcinoma (HCC) has not yet

237 Therefore, studies about the prognosis of HGSC may provide therapeutic avenues to imp

238 at potentials as biomarker for diagnosis and prognosis of human cancers.

239 characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic

240 emethylases influence the viability and poor prognosis of neuroblastoma cells, where MYC is often ove

241 tide (NT-proBNP) concentration predicts poor prognosis of non-CNS cancer patients.

242 of oxidative stress on chemosensitivity and prognosis of ovarian cancer patients.

243 Poor prognosis of ovarian cancer, the deadliest of the gyneco

244 ed fibroblasts (CAFs) contribute to the poor prognosis of ovarian cancer.

245 The clinical features and long-term prognosis of patients who underwent AHSCT and test posit

246 c balloon pump counterpulsation therapy, the prognosis of patients with cardiogenic shock has remaine

247 This study investigated the long-term prognosis of patients with intermediate-risk PE and the

248 The spontaneous prognosis of patients with sALI/ALF due to DRESS is poor

249 We aimed to determine whether the prognosis of patients with treated versus untreated depr

250 signaling-related genes correlated with the prognosis of pediatric patients with pre-B-ALL, and fast

251 protein level has been associated with poor prognosis of several types of cancers.

252 on and thus affect radiotherapy response and prognosis of squamous cell carcinoma of oropharynx (SCCO

253 y suggesting that genomic instability drives prognosis of the disease.

254 seems to be acceptable considering the poor prognosis of the eligible patients.

255 Prognosis of these patients is therefore reliant upon a

256 d to inadequate management and influence the prognosis of these patients.

257 and the patient was explained about the poor prognosis of this condition.

258 This study evaluated the prognosis of using standard alloplastic TMJ prostheses f

259 ic chips has critical significance in cancer prognosis offering a non-invasive "liquid biopsy".

260 dictive mathematical model designed to guide prognosis on the basis of clinical features present at d

261 ive of treatment, was associated with better prognosis only for patients in sinus rhythm (HR: 1.16 pe

262 R-200b editing level correlates with patient prognosis opposite to the pattern observed for the wild-

263 generation, for example in estimating visual prognosis or highlighting the importance of developing t

264 types, correlated with drug response, tumor prognosis, or patient survival.

265 s with predictive value for early diagnosis, prognosis, or relapse and a thorough characterization of

266 olymorphisms influence the onset of disease, prognosis, or response to treatment.

267 th basal-like breast cancer (BLBC) with poor prognosis owing to its role in promoting epithelial-to-m

268 provides a comprehensive picture of patient prognosis, particularly for older patients with ST-segme

269 e of chromothripsis and associated with poor prognosis per se and not merely by association with othe

270 machine-learning readable format, we built a prognosis predictor model to predict the outcome of trea

271 Based on these emerging concepts, the prognosis, quality of life, and survival of patients wit

272 Brain invasion by glioblastoma determines prognosis, recurrence, and lethality in patients, but no

273 suppression in GBM also correlates with poor prognosis, reduces GBM cell migration and invasiveness b

274 BUB1B(S) patients have a significantly worse prognosis regardless of tumor development subtype (i.e.,

275 nal benefit over that to ranibizumab, visual prognosis remains limited.

276 ); in contrast, in RAS wt patients with poor-prognosis right-sided tumors, limited efficacy benefits

277 rved, we developed a continuous quantitative prognosis score (Continuous Linear Enhanced Assessment o

278 enetic deletion occurs predominantly in poor prognosis serous subtype tumours, and this genetic delet

279 sk of bias was assessed using the Quality in Prognosis Studies system.

280 a karyotypically complex and especially poor-prognosis subtype that accounts for less than 10% of lip

281 lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear.

282 EMZL, FL, and MF had a significantly better prognosis than MCL and DLBCL.

283 ve less-severe disease and may have a better prognosis than obese patients.

284 yocardial segment is associated with a worse prognosis than other patterns of presentation.

285 with left-sided tumors had a markedly better prognosis than those with right-sided tumors.

286 kers of inflammation predict HF severity and prognosis that may complement or even outperform traditi

287 Most cases of thyroid cancer have a good prognosis; the 5-year survival rate for thyroid cancer o

288 on on the presence of osseous metastasis and prognosis to assist patients and their physicians when m

289 most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape.

290 activity was observed in patients with poor-prognosis tumors.

291 or less extensive disease for POM; and worse prognosis versus no change or better prognosis for TM, b

292 M-derived parameters in predicting long-term prognosis was evaluated.

293 Her prognosis was extremely grim; her family gathered in ant

294 iant will help clinicians with diagnosis and prognosis when treating new patients.

295 d with luminal breast cancer (LBC) with good prognosis, whereas Twist1 expression is associated with

296 ssion was significantly correlated with poor prognosis while patients with low BMP4 or low Smad4 immu

297 Gastric cancer (GC) has a poor prognosis with wide variation in survival rates across t

298 t 3 also performed well in predicting a good prognosis, with AUC of 0.767, 0.857 and 0.820, respectiv

299 uations in which containment will make a bad prognosis worse.

300 In the validation cohort, prognosis worsened with increasing HALT-HCC score (5-yea